Drug Patents owned by Cephalon

1. Drug name - FENTORA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8092832 CEPHALON Generally linear effervescent oral fentanyl dosage form and methods of administering Dec, 2024

(2 years from now)

US8119158 CEPHALON Effervescent oral fentanyl dosage form and methods of administering fentanyl Dec, 2024

(2 years from now)

US7862833 CEPHALON Effervescent oral opiate dosage forms and methods of administering opiates Jun, 2028

(5 years from now)

US7862832 CEPHALON Generally linear effervescent oral fentanyl dosage form and methods of administering Jun, 2028

(5 years from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Treatment: NA

Dosage: TABLET;BUCCAL, SUBLINGUAL

More Information on Dosage
Strength Dosage Availability
EQ 0.1MG BASE TABLET;BUCCAL, SUBLINGUAL Prescription
EQ 0.2MG BASE TABLET;BUCCAL, SUBLINGUAL Prescription
EQ 0.3MG BASE TABLET;BUCCAL, SUBLINGUAL Discontinued
EQ 0.4MG BASE TABLET;BUCCAL, SUBLINGUAL Prescription
EQ 0.6MG BASE TABLET;BUCCAL, SUBLINGUAL Prescription
EQ 0.8MG BASE TABLET;BUCCAL, SUBLINGUAL Prescription

2. Drug name - NUVIGIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7132570 CEPHALON Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
Dec, 2023

(1 year, 2 months from now)

CN1751021A CEPHALON Crystal Form Of Modafinil Optical Enantiomer And Its Preparation Method
Dec, 2018

(3 years ago)

CN101012189B CEPHALON Crystalline Forms And Crystalline Forms Of Optical Enantiomers Of Modafinil And Method For The Procution Same
Dec, 2018

(3 years ago)

CN100540533C CEPHALON Crystalline Forms And Crystalline Forms Of Optical Enantiomers Of Modafinil And Method For The Procution Same
Dec, 2018

(3 years ago)

CN101012189A CEPHALON Crystal Form Of Modafinil Optical Enantiomer And Its Preparation Method
Dec, 2018

(3 years ago)

IN200501304P4 CEPHALON Process For The Preperation Of And
Dec, 2023

(1 year, 2 months from now)

IN256037B CEPHALON A Process For The Preperation Of Crystalline Forms Of The Optical Enantiomers Of Modafinil
Dec, 2023

(1 year, 2 months from now)

EP1572635A1 CEPHALON Method For The Production Of Crystalline Forms And Crystalline Forms Of Optical Enantiomers Of Modafinil
Dec, 2023

(1 year, 2 months from now)

EP2343275A3 CEPHALON Process For The Preparation And Crystalline Form I Of The Optical Enantiomers Of Modafinil
Dec, 2023

(1 year, 2 months from now)

EP2679578A3 CEPHALON Preparation Method And Crystalline Form Of Optical Enantiomers Of Modafinil
Dec, 2023

(1 year, 2 months from now)

EP2343275B1 CEPHALON Crystalline Form Of The Optical Enantiomers Of Modafinil
Dec, 2023

(1 year, 2 months from now)

EP2679578A2 CEPHALON Preparation Method And Crystalline Form Of Optical Enantiomers Of Modafinil
Dec, 2023

(1 year, 2 months from now)

EP1572635B1 CEPHALON Method For The Production Of Crystalline Forms And Crystalline Forms Of Optical Enantiomers Of Modafinil
Dec, 2023

(1 year, 2 months from now)

EP2343275A2 CEPHALON Crystalline Form Of The Optical Enantiomers Of Modafinil
Dec, 2023

(1 year, 2 months from now)

EP2679578B1 CEPHALON Preparation Method And Crystalline Form Of Optical Enantiomers Of Modafinil
Dec, 2023

(1 year, 2 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7297346 CEPHALON Pharmaceutical formulations of modafinil Nov, 2023

(1 year, 1 month from now)

US7297346

(Pediatric)

CEPHALON Pharmaceutical formulations of modafinil May, 2024

(1 year, 7 months from now)

US7132570

(Pediatric)

CEPHALON Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil Jun, 2024

(1 year, 8 months from now)

More Information on Dosage
Strength Dosage Availability
50MG TABLET;ORAL Prescription
100MG TABLET;ORAL Discontinued
150MG TABLET;ORAL Prescription
200MG TABLET;ORAL Prescription
250MG TABLET;ORAL Prescription

3. Drug name - PROVIGIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7297346 CEPHALON Pharmaceutical formulations of modafinil Nov, 2023

(1 year, 1 month from now)

US7297346

(Pediatric)

CEPHALON Pharmaceutical formulations of modafinil May, 2024

(1 year, 7 months from now)

Drugs and Companies using MODAFINIL ingredient

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
100MG TABLET;ORAL Prescription
200MG TABLET;ORAL Prescription

4. Drug name - TREANDA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8445524 CEPHALON Solid forms of bendamustine hydrochloride
Mar, 2029

(6 years from now)

CN105693620A CEPHALON Bendamustine Hydrochloride Solid Form
Sep, 2018

(4 years ago)

CN101980698A CEPHALON Novel Solid Forms Of Bendamustine Hydrochloride
Mar, 2029

(6 years from now)

CN103550159B CEPHALON Bendamustine Hydrochloride In Solid Form
Mar, 2029

(6 years from now)

CN103550159A CEPHALON Solid Form Hydrochloric Bendamustine
Mar, 2029

(6 years from now)

CN101980698B CEPHALON Solid Forms Of Bendamustine Hydrochloride
Mar, 2029

(6 years from now)

EP2271315A2 CEPHALON Solid Forms Of Bendamustine Hydrochloride
Mar, 2029

(6 years from now)

EP2271315B1 CEPHALON Solid Forms Of Bendamustine Hydrochloride
Mar, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895756 CEPHALON Bendamustine pharmaceutical compositions Jan, 2026

(3 years from now)

US8609863 CEPHALON Bendamustine pharmaceutical compositions Jan, 2026

(3 years from now)

US8791270 CEPHALON Bendamustine pharmaceutical compositions Jan, 2026

(3 years from now)

US8609863

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions Jul, 2026

(3 years from now)

US8791270

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions Jul, 2026

(3 years from now)

US8895756

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions Jul, 2026

(3 years from now)

US8883836 CEPHALON Solid forms of bendamustine hydrochloride Mar, 2029

(6 years from now)

US9533955 CEPHALON Solid forms of bendamustine hydrochloride Mar, 2029

(6 years from now)

US8669279 CEPHALON Solid forms of bendamustine hydrochloride Mar, 2029

(6 years from now)

US8344006 CEPHALON Liquid formulations of bendamustine Sep, 2029

(6 years from now)

US8445524

(Pediatric)

CEPHALON Solid forms of bendamustine hydrochloride Sep, 2029

(6 years from now)

US8883836

(Pediatric)

CEPHALON Solid forms of bendamustine hydrochloride Sep, 2029

(6 years from now)

US8669279

(Pediatric)

CEPHALON Solid forms of bendamustine hydrochloride Sep, 2029

(6 years from now)

US8344006

(Pediatric)

CEPHALON Liquid formulations of bendamustine Mar, 2030

(7 years from now)

US8436190 CEPHALON Bendamustine pharmaceutical compositions Oct, 2030

(8 years from now)

US8436190

(Pediatric)

CEPHALON Bendamustine pharmaceutical compositions Apr, 2031

(8 years from now)

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Treatment: For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma; For use in the treatment of patients with chronic lymphocytic leukemia (cll) and/or indolent b-cell non-hodgkin lymphoma (nhl); For use in the treatment of patients with indolent b-cell non-hodgkin lymphoma; for use in the treatment of patients with chronic lymphocytic leukemia (cll)

Dosage: POWDER;IV (INFUSION); SOLUTION;IV (INFUSION)

More Information on Dosage
Strength Dosage Availability
25MG/VIAL POWDER;IV (INFUSION) Prescription
100MG/VIAL POWDER;IV (INFUSION) Prescription
45MG/0.5ML (90MG/ML) SOLUTION;IV (INFUSION) Discontinued
180MG/2ML (90MG/ML) SOLUTION;IV (INFUSION) Discontinued

availability in other generic markets.

Click on the highlighted region to filter.